Insulet (GOV) Q2 2026 Earnings Report

The call conveyed a broadly positive operational and financial performance — strong revenue, significant margin expansion, robust EPS growth, international strength, product and clinical progress, and solid liquidity — while transparently acknowledging a meaningful, addressable execution issue in onboarding and retaining type 2 customers that led to a modest downward revision to U.S. revenue outlook and a reassessment of longer-term assumptions. Management presented concrete actions (expanded customer care, sales compensation changes, sampling refinements, Omnipod Discover and data platform investments) to remediate retention and utilization in the first 90 days and expressed confidence these will translate into improved outcomes over time.

Insulet updated 2026 guidance to expect full‑year constant‑currency total company revenue growth of 20–22% and total Omnipod growth of 21–23%, with U.S. Omnipod up 17–19% and international Omnipod up 30–32% (FX expected to add ~100 bps to total/company Omnipod growth and ~300 bps to international); Q3 guidance calls for Omnipod growth of 18–20% and total company growth of 17.5–19.5% (U.S. Omnipod 14–16%, international Omnipod 28–30%) with FX headwinds of ~50 bps to Q3 totals and ~200 bps to international, management still expects ~100 bps of operating‑margin expansion in 2026, roughly $40M of net interest expense, a non‑GAAP tax rate of 20–21%, ~70M shares outstanding, adjusted EPS growth of at least 30% for the year, free cash flow modestly down versus 2025 (YTD FCF $145M) and an exit‑rate into year‑end in the mid‑teens constant‑currency that the company aims to meet or exceed in 2027 (preliminary view assumes competition but not benefits from newly deployed retention actions).